Cuprina Holdings (Cayman) Ltd（CUPR）股票分析CUPRCuprina Holdings (Cayman) Ltd

Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment. It operates in the Healthcare sector.

Cuprina Holdings (CUPR) is currently trading at a price of 3.01, which is significantly lower than its 1-year change of -57.64%. The RSI is at 52.413, indicating a neutral momentum. However, the forward P/E ratio is 0, suggesting a lack of earnings expectations, and the gross margin is negative at -6.26%. While there was a recent surge of 47% due to FDA clearance for a product, the overall financial performance shows substantial losses with a net margin of -9366.75% projected for 2025/Q4. The main risk is the high volatility and lack of consistent positive financial indicators, which could lead to further declines.